IRWD Share Price

Open 16.70 Change Price %
High 17.26 1 Day 0.12 0.72
Low 16.48 1 Week 0.02 0.12
Close 16.89 1 Month 1.82 12.08
Volume 1856497 1 Year 6.65 64.94
52 Week High 17.49
52 Week Low 9.06
IRWD Important Levels
Resistance 2 17.61
Resistance 1 17.32
Pivot 16.88
Support 1 16.46
Support 2 16.17
NASDAQ USA Most Active Stocks
STLD 36.60 -0.27%
STLD 36.60 -0.27%
BEAV 63.60 -0.33%
VCIT 86.62 -0.01%
FTR 2.93 -10.94%
FTR 2.93 -10.94%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
DRYS 2.06 10.16%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PBMD 2.93 22.59%
NTRI 46.50 18.62%
LIFE 4.00 15.94%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 5
As on 28th Feb 2017 IRWD Share Price closed @ 16.89 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 13.87 & Strong Buy for SHORT-TERM with Stoploss of 15.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for March
1st Target up-side 18.59
2nd Target up-side 19.78
3rd Target up-side 20.97
1st Target down-side 15.19
2nd Target down-side 14
3rd Target down-side 12.81
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.